AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Exclusion Criteria

• •Subjects believed to be a higher than average risk of bowel perforation. This includes symptoms of partial or complete bowel obstruction, recent (within 6 months) history of fistula or bowel perforation, subjects requiring total parenteral nutrition and continuous hydration
• •Previous abdominal /or pelvic external beam radiotherapy
• •Known history of central nervous system metastases
• •Subjects with a history of prior malignancy, except:
• •* Malignancy treated with curative intent and with no known active disease present for \>= 3 years before study day 1 and felt to be at low risk for recurrence by treating physician
• •* Adequately treated non melanomatous skin cancer or lentigo maligna without evidence of disease
• •* Adequately treated cervical carcinoma in situ without evidence of disease
• •Prior myeloablative high dose chemotherapy with allogeneic or autologous stem cell (or bone marrow) transplant
• •History of arterial or deep venous thromboembolism within 12 months prior to enrollment
• •Clinically significant cardiac disease within 12 months prior to enrollment
• •Prior treatment with doxorubicin or pegylated liposomal doxorubicin (cohort A subjects) and topotecan (cohort B subjects)
• •Current or within 30 days prior to enrollment treatment with immune modulators such as systemic cyclosporine and tacrolimus